Clinical Trial: Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Randomized, Placebo-Controlled, Double Blind, Phase 1 Trial of the Safety, Immunogenicity, and Tolerability of Ascending Doses of Meningococcal Group B rLP2086 Vaccine in Healthy Adults
Brief Summary: To determine the safety & immunogenicity of a potential vaccine against meningococcal B disease
Detailed Summary:
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Current Primary Outcome: Local & systemic safety throughout the trial
Original Primary Outcome: Same as current
Current Secondary Outcome: Evidence of an immune response 1 month after dose 2 & 1 month after dose 3
Original Secondary Outcome: Same as current
Information By: Wyeth is now a wholly owned subsidiary of Pfizer
Dates:
Date Received: February 24, 2006
Date Started: March 2006
Date Completion:
Last Updated: December 3, 2007
Last Verified: December 2007